ALPS Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-2,901
| Closed | -$396K | – | 1082 |
|
|
2024
Q4 | $396K | Hold |
2,901
| – | – | ﹤0.01% | 697 |
|
|
2024
Q3 | $334K | Buy |
2,901
+410
| +16% | +$47.2K | ﹤0.01% | 909 |
|
|
2024
Q2 | $343K | Sell |
2,491
-15
| -0.6% | -$2.07K | ﹤0.01% | 758 |
|
|
2024
Q1 | $346K | Sell |
2,506
-409
| -14% | -$56.4K | ﹤0.01% | 851 |
|
|
2023
Q4 | $384K | Sell |
2,915
-165
| -5% | -$21.7K | ﹤0.01% | 705 |
|
|
2023
Q3 | $347K | Buy |
+3,080
| New | +$347K | ﹤0.01% | 670 |
|
|
2020
Q3 | – | Sell |
-2,542
| Closed | -$310K | – | 902 |
|
|
2020
Q2 | $310K | Sell |
2,542
-282
| -10% | -$34.4K | ﹤0.01% | 551 |
|
|
2020
Q1 | $244K | Buy |
+2,824
| New | +$244K | ﹤0.01% | 591 |
|
|
2017
Q2 | – | Sell |
-74,944
| Closed | -$3.25M | – | 781 |
|
|
2017
Q1 | $3.25M | Sell |
74,944
-8,538
| -10% | -$370K | 0.02% | 156 |
|
|
2016
Q4 | $3.23M | Sell |
83,482
-27,113
| -25% | -$1.05M | 0.02% | 151 |
|
|
2016
Q3 | $5.6M | Sell |
110,595
-11,139
| -9% | -$564K | 0.05% | 132 |
|
|
2016
Q2 | $5.53M | Buy |
121,734
+24,508
| +25% | +$1.11M | 0.05% | 122 |
|
|
2016
Q1 | $3.85M | Sell |
97,226
-16,325
| -14% | -$646K | 0.04% | 127 |
|
|
2015
Q4 | $6.42M | Sell |
113,551
-20,860
| -16% | -$1.18M | 0.06% | 115 |
|
|
2015
Q3 | $53.5K | Buy |
134,411
+49,638
| +59% | +$19.8K | 0.06% | 109 |
|
|
2015
Q2 | $4.05M | Buy |
84,773
+43,292
| +104% | +$2.07M | 0.03% | 130 |
|
|
2015
Q1 | $1.65M | Buy |
+41,481
| New | +$1.65M | 0.01% | 158 |
|